# Viscogliosi Brothers

> Viscogliosi Brothers is a VC fund in New York backing Medical and Health Care. See 10 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 10
- Last investment: Mar 2023
- Lead investor: 70%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/viscogliosi-bros-llc./
- Website: http://www.vbllc.com

Viscogliosi Brothers is a private equity and merchant banking firm specialized in the orthopedics sector of the healthcare industry.

## Contacts

5 contacts available for Viscogliosi Brothers. Shizune tracks 3 team members at Viscogliosi Brothers. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/viscogliosi-brothers?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 3 | 30% |
| Health Care | 3 | 30% |
| Biotechnology | 2 | 20% |
| Manufacturing | 2 | 20% |
| Medical Device | 2 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 20% |
| Series B | 2 | 20% |
| Series C | 1 | 10% |
| Series D | 1 | 10% |
| Series F | 1 | 10% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 4 | 40% |
| France | 1 | 10% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| John Viscogliosi | Founding Member and Principal | 0 | — |
| Anthony G. Viscogliosi | Principal & Co-Founder | 0 | — |
| Marc R. Viscogliosi | Founder & Principal | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Companion Spine | Companion Spine provides interventional therapies and technologies to ensure back pain is resolved with minimal disruption, less pain, and Safer to people's quality of life. | $5M | Series A | Mar 23, 2023 |  |
| Spine BioPharma | Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $13M | Convertible Note | Feb 08, 2023 |  |
| Spine BioPharma | Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $13M | Series B | Mar 23, 2022 |  |
| Companion Spine | Companion Spine provides interventional therapies and technologies to ensure back pain is resolved with minimal disruption, less pain, and Safer to people's quality of life. | $55M | Series A | Feb 15, 2022 |  |
| Spine BioPharma | Spine BioPharma develops a non-surgical solution for back pain that will eliminate pain and restore functionality, without the use of opioids. The company's pipeline of therapeutic treatments targets the clinical benefits of reducing pain, restoring function and slowing or stopping pathological disease progression. Its mission is to improvethe lives of millions of individuals suffering every day from degenerative spine diseases by delivering clinically proven, safe, and effective therapies that inhibit pain and inflammation, and restores quality of life. | $5M | Series A | Mar 12, 2021 |  |
| Small Bone Innovations | Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $15M | Series F | Dec 17, 2010 |  |
| Small Bone Innovations | Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $36M | Series C | Jan 01, 2008 |  |
| Small Bone Innovations | Small Bones Innovations (SBi) makes devices for small bones and joints, particularly focusing on trauma and arthroplasty. | $42.2M | Series B | Dec 16, 2005 |  |
| Spine Next | Spine Next is a biotech company that manufactures and markets orthopedic spinal implant devices for spinal fusion surgeries. Spine Next is a France-based company that was founded in 1999 and the company was acquired by Abbott on October 25, 2004. | $2M | Series D | Mar 10, 2004 |  |
| Raymedica | Raymedica, Inc. is an emerging medical device manufacturer with headquarters in Minneapolis, Minnesota. Raymedica’s goal is to develop innovative solutions for the surgical treatment of patients with low back pain who have not responded to conservative care, thus improving the quality of life for these patients worldwide. This mission isaccomplished by expanding and improving the technology invented by Raymedica’s founder, Charles D. Ray, M.D. Currently, the company’s efforts are devoted to the development of the PDN® prosthetic disc nucleus for the treatment of low back pain associated with degenerative disc disease. The PDN device is surgically implanted into the evacuated nucleus disc space of the lumbar spine. Once implanted, the device is intended to increase or maintain disc height thereby restoring normal biomechanics, thus relieving pain. | $10M |  | Oct 24, 2003 |  |

10 of 10 investments shown.

## Co-investors
- [NGN Capital](https://shizune.co/investors/profile/ngn-capital) — VC Fund, 3 deals together
- [3i Group](https://shizune.co/investors/profile/3i-group) — VC Fund, 2 deals together
- [Axiom Ventures](https://shizune.co/investors/profile/axiom-ventures) — VC Fund, 2 deals together
- [Cercano Management](https://shizune.co/investors/profile/cercano-management) — VC Fund, 2 deals together
- [Pacira Pharmaceuticals](https://shizune.co/investors/profile/pacira-pharmaceuticals) — VC Fund, 2 deals together
- Chartwell Capital — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Viscogliosi Brothers invest in?

Viscogliosi Brothers invests primarily in Medical, Health Care and Biotechnology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Viscogliosi Brothers?

Public channels for Viscogliosi Brothers include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Viscogliosi Brothers?

The team at Viscogliosi Brothers includes John Viscogliosi (Founding Member and Principal), Anthony G. Viscogliosi (Principal & Co-Founder) and Marc R. Viscogliosi (Founder & Principal). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co